Skip to main content

Table 4 Multivariate analysis of prognostic factors

From: Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer

Variable HR 95% CI p value
GPS = 0 0.47 0.29–0.76 < 0.002
CEA ≤ 10 ng/mL 0.47 0.29–0.78 < 0.003
  1. CEA carcinoembryonic antigen, CI confidence interval, HR hazard ratio, GPS Glasgow prognostic score